Waverton Investment Management Ltd raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,426 shares of the company’s stock after buying an additional 851 shares during the quarter. Waverton Investment Management Ltd’s holdings in Johnson & Johnson were worth $2,295,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Harding Loevner LP acquired a new position in shares of Johnson & Johnson during the second quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson during the second quarter valued at about $124,000. Lenox Wealth Management Inc. increased its holdings in shares of Johnson & Johnson by 1.7% during the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after acquiring an additional 24 shares in the last quarter. Finally, Intercontinental Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson during the second quarter valued at about $200,000. 67.21% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Several equities analysts have recently issued reports on JNJ shares. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective on the stock in a report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Stifel Nicolaus upped their price objective on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Wells Fargo restated an “outperform” rating and set a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Finally, Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and a consensus target price of $146.06.

In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.19% of the stock is owned by company insiders.

Johnson & Johnson (NYSE:JNJ) opened at $127.38 on Friday. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. The firm has a market cap of $351,969.94, a P/E ratio of 17.97, a P/E/G ratio of 2.09 and a beta of 0.77.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The business’s revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the company earned $1.58 EPS. analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were paid a dividend of $0.84 per share. The ex-dividend date of this dividend was Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.64%. Johnson & Johnson’s payout ratio is 861.54%.

TRADEMARK VIOLATION NOTICE: “Waverton Investment Management Ltd Has $2.30 Million Holdings in Johnson & Johnson (JNJ)” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/waverton-investment-management-ltd-has-2-30-million-holdings-in-johnson-johnson-jnj/1959797.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.